First-in-human Erda-iDRS (formerly TAR-210) results in intermediate‑risk NMIBC highlighted March 17, 2026
Tazverik® (tazemetostat) voluntarily withdrawn in follicular lymphoma and epithelioid sarcoma March 17, 2026
ProstACT Ph 3 Study (Part 1) of TLX591-Tx Achieves Primary Objectives in PSMA+ve metastatic CRPC Patients March 17, 2026
Type A meeting with FDA scheduled to discuss the CRL to the BLA for tabelecleucel (tab-cel) March 17, 2026
Results from PIK3CA WT Cohort of Ph 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer Published in Journal of Clinical Oncology March 17, 2026
Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported March 17, 2026
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% March 17, 2026
Combo Regimen May Improve Pathologic Complete Response Rate in TNBC in Early Ph 2 INVINCIBLE-4 of INT230-6 March 17, 2026
FDA granted Orphan Drug Designation to AMXT 1501 in combination with difluoromethylornithine (DFMO) for the treatment of malignant glioma March 17, 2026
Imfinzi approved in the EU in patients with early gastric and gastroesophageal cancers March 17, 2026
